Erica Lee, PhD, is the CEO and Co-Founder of NervMyo Therapeutics and an MD/PhD candidate at Johns Hopkins. She has spent the past seven years developing the company’s core technology as part of her thesis work, securing $30K in funding, publishing 10 peer-reviewed papers, filing 3 patents, and winning major startup competitions including the Nucleate Regional Activator (2024) and Student Venture Showcase (2025).
NervMyo Therapeutics is advancing a nanoparticle-based delivery system for sustained, localized release of IGF-1, designed to enhance nerve regeneration and preserve muscle function after peripheral nerve injury. The platform has shown robust efficacy in small and large animal models and is now moving into preclinical safety studies.
With no FDA-approved therapies to accelerate nerve repair, NervMyo’s first-to-market technology integrates with existing surgical procedures and targets high-need indications—including traumatic nerve injuries, carpal tunnel syndrome, and cancer-related neuropathies—offering a breakthrough in regenerative medicine.
